Our network meta-analysis based on RCTs showed that trastuzumab emtansine was the drug compared most frequently, and among several anti-HER2 regimens for the treatment of patients with brain metastases from breast cancer, trastuzumab deruxtecan was the most effective. The gene discussed is ERBB2; the disease is breast carcinoma.